TY - JOUR
T1 - Full-spectrum Cannabis sativa extract enhances gut-peripheral organ integrity after experimental ischemic stroke
AU - de Souza Stork, Solange
AU - Mathias, Khiany
AU - Gava, Fernanda
AU - Joaquim, Larissa
AU - dos Santos, David
AU - Tiscoski, Anita Dal Bó
AU - Bonfante, Sandra
AU - Strickert, Yasmin Ribeiro
AU - Machado, Richard Simon
AU - Martins, Helena Mafra
AU - Chaves, Jéssica Schaefer
AU - Generoso, Jaqueline
AU - Danielski, Lucineia Gainski
AU - Giustina, Amanda Della
AU - Scussel, Rahisa
AU - Bitencourt, Rafael
AU - Mack, Josiel Mileno
AU - de Souza Goldim, Mariana Pereira
AU - Machado-de-Ávila, Ricardo Andrez
AU - Barichello, Tatiana
AU - Bobinski, Franciane
AU - Petronilho, Fabricia
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2025.
PY - 2025
Y1 - 2025
N2 - Objective: This study aims to investigate the impact of full-spectrum Cannabis sativa extract (FSC) treatment on gut and peripheral organ protection after ischemic stroke. Main methods: Male Wistar rats were subjected to 60-min middle cerebral artery occlusion (MCAO) or sham surgery, and received FSC (15 or 30 mg/kg) or coconut oil by gavage at different time points post-MCAO. After 72 h, neurological score, infarct volume, blood cell count, thymus, spleen and adrenal gland size and weight, serum corticosterone, intestinal permeability, oxidative stress, and inflammatory cytokines in peripheral organs were assessed. Key findings: The results show a significant improvement in neurological deficits, suggesting the therapeutic potential of FSC in post-stroke recovery. Additionally, a reduction in body mass, a decrease in blood cells related to the immune response, and atrophy of lymphoid organs, lower corticosterone levels, and reduced intestinal permeability were observed. FSC treatment also demonstrated a crucial role in protecting against oxidative stress and post-stroke lung inflammation. Significance: The discovery of the positive impacts of FSC in this study represents an entry point for new explorations and perspectives within this field. With latent potential, these findings have the power to shape clinical research, especially in the realm of neurodegenerative diseases and innovative therapies. Therefore, the results highlight the promising role of FSC, paving the way for more effective and transformative clinical interventions.
AB - Objective: This study aims to investigate the impact of full-spectrum Cannabis sativa extract (FSC) treatment on gut and peripheral organ protection after ischemic stroke. Main methods: Male Wistar rats were subjected to 60-min middle cerebral artery occlusion (MCAO) or sham surgery, and received FSC (15 or 30 mg/kg) or coconut oil by gavage at different time points post-MCAO. After 72 h, neurological score, infarct volume, blood cell count, thymus, spleen and adrenal gland size and weight, serum corticosterone, intestinal permeability, oxidative stress, and inflammatory cytokines in peripheral organs were assessed. Key findings: The results show a significant improvement in neurological deficits, suggesting the therapeutic potential of FSC in post-stroke recovery. Additionally, a reduction in body mass, a decrease in blood cells related to the immune response, and atrophy of lymphoid organs, lower corticosterone levels, and reduced intestinal permeability were observed. FSC treatment also demonstrated a crucial role in protecting against oxidative stress and post-stroke lung inflammation. Significance: The discovery of the positive impacts of FSC in this study represents an entry point for new explorations and perspectives within this field. With latent potential, these findings have the power to shape clinical research, especially in the realm of neurodegenerative diseases and innovative therapies. Therefore, the results highlight the promising role of FSC, paving the way for more effective and transformative clinical interventions.
KW - Cannabidiol
KW - Gut
KW - Ischemic stroke
KW - Neuroprotection
KW - Peripheral organs
UR - http://www.scopus.com/inward/record.url?scp=105005534432&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105005534432&partnerID=8YFLogxK
U2 - 10.1007/s10787-025-01775-1
DO - 10.1007/s10787-025-01775-1
M3 - Article
C2 - 40389682
AN - SCOPUS:105005534432
SN - 0925-4692
JO - Inflammopharmacology
JF - Inflammopharmacology
M1 - 103956
ER -